## Qi Xue

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4830833/publications.pdf

Version: 2024-02-01

		361045	315357
112	2,260	20	38
papers	citations	h-index	g-index
100	100	100	2072
120	120	120	2073
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Journal of Cancer Research and Clinical Oncology, 2022, 148, 943-954.	1.2	21
2	Outcomes and experience of anatomical partial lobectomy. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 637-647.e1.	0.4	9
3	Plasma extracellular vesicle microRNA profiling and the identification of a diagnostic signature for stage I lung adenocarcinoma. Cancer Science, 2022, 113, 648-659.	1.7	16
4	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. Npj Precision Oncology, 2022, 6, 2.	2.3	17
5	Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis. Frontiers in Immunology, 2022, 13, 783495.	2.2	13
6	Adenoid Cystic Carcinoma of Lobar Bronchial Origin: 20-Year Experience at a Single Institution. Annals of Surgical Oncology, 2022, 29, 4408-4416.	0.7	7
7	High-Precision Intelligent Cancer Diagnosis Method: 2D Raman Figures Combined with Deep Learning. Analytical Chemistry, 2022, 94, 6491-6501.	3.2	18
8	27-hydroxycholesterol linked high cholesterol diet to lung adenocarcinoma metastasis. Oncogene, 2022, , .	2.6	10
9	Sintilimab for the treatment of non-small cell lung cancer. Biomarker Research, 2022, 10, 23.	2.8	16
10	Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2022, 17, 909-920.	0.5	28
11	Dissecting transcriptional heterogeneity in multiple primary lung cancer by single cell RNA sequencing Journal of Clinical Oncology, 2022, 40, e20516-e20516.	0.8	O
12	Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): An open-label, randomized, phase 2 study Journal of Clinical Oncology, 2022, 40, 4031-4031.	0.8	1
13	An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection Journal of Clinical Oncology, 2022, 40, 3037-3037.	0.8	O
14	<i>KRAS</i> à€G12D mutation drives immune suppression and the primary resistance of antiâ€PDâ€1/PDâ€L1 immunotherapy in nonâ€small cell lung cancer. Cancer Communications, 2022, 42, 828-847.	3.7	29
15	Pulmonary resection for multiple lung metastasis from ameloblastoma: a rare case report and literature review. Postgraduate Medicine, 2021, 133, 117-122.	0.9	2
16	Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort. Annals of Surgical Oncology, 2021, 28, 3941-3950.	0.7	69
17	Association of phosphoenolpyruvate carboxykinase 1 protein kinase activity-dependent sterol regulatory element-binding protein 1 activation with prognosis of oesophageal carcinoma. European Journal of Cancer, 2021, 142, 123-131.	1.3	11
18	Liquid biopsy for esophageal cancer: Is detection of circulating cellâ€free DNA as a biomarker feasible?. Cancer Communications, 2021, 41, 3-15.	3.7	10

#	Article	IF	CITATIONS
19	Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non–small-cell Lung Cancer: A Propensity Score Matching Study. Clinical Lung Cancer, 2021, 22, e201-e210.	1.1	19
20	Uniportal videoâ€essisted thoracoscopic left pneumonectomy: Retrospective analysis of eighteen consecutive patients from a single center. Thoracic Cancer, 2021, 12, 324-328.	0.8	0
21	The prognostic value of tumor deposits and the impact on the TNM classification system in esophageal cancer patients. Journal of Surgical Oncology, 2021, 123, 891-903.	0.8	4
22	Log odds of positive lymph nodes is a better prognostic factor for oesophageal signet ring cell carcinoma than N stage. World Journal of Clinical Cases, 2021, 9, 24-35.	0.3	1
23	Development of a nomogram for predicting the operative mortality of patients who underwent pneumonectomy for lung cancer: a population-based analysis. Translational Lung Cancer Research, 2021, 10, 381-391.	1.3	9
24	A rare case of primary pulmonary inflammatory pseudotumor-like follicular dendritic cell sarcoma successfully treated by lobectomy. Annals of Translational Medicine, 2021, 9, 77-77.	0.7	5
25	Clinicopathological characteristics and prognostic factors of primary pulmonary lymphoma. Journal of Thoracic Disease, 2021, 13, 1106-1117.	0.6	10
26	The value of multidisciplinary team (MDT) management in the diagnosis and treatment of primary intrathoracic synovial sarcomas: a single-center experience. Journal of Thoracic Disease, 2021, 13, 600-612.	0.6	7
27	Therapeutic options for resectable second lung tumor after previous pneumonectomy: a SEER database analysis. Annals of Palliative Medicine, 2021, 10, 1866-1879.	0.5	0
28	Nomogram for predicting the overall survival of the patients with oesophageal signet ring cell carcinoma. Journal of Thoracic Disease, 2021, 13, 1315-1326.	0.6	0
29	A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology, 2021, 9, 651406.	1.8	30
30	Development and Validation of a Nomogram Prognostic Model for Resected Limited-Stage Small Cell Lung Cancer Patients. Annals of Surgical Oncology, 2021, 28, 4893-4904.	0.7	12
31	Comprehensive Analysis of Ferroptosis Regulators in Lung Adenocarcinomas Identifies Prognostic and Immunotherapy-Related Biomarkers. Frontiers in Molecular Biosciences, 2021, 8, 587436.	1.6	13
32	The surgical management of early-stage lung adenocarcinoma: is wedge resection effective?. Journal of Thoracic Disease, 2021, 13, 2137-2147.	0.6	2
33	Lobectomy vs. sublobectomy for stage I non-small-cell lung cancer: a meta-analysis. Annals of Translational Medicine, 2021, 9, 751-751.	0.7	3
34	Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer Journal of Clinical Oncology, 2021, 39, 3028-3028.	0.8	1
35	Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 3651-3667.	2.0	14
36	Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review. Targeted Oncology, 2021, 16, 425-434.	1.7	16

#	Article	IF	CITATIONS
37	Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC Journal of Clinical Oncology, 2021, 39, 8522-8522.	0.8	4
38	Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade Journal of Clinical Oncology, 2021, 39, 9063-9063.	0.8	0
39	Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma. Frontiers in Immunology, 2021, 12, 669750.	2.2	45
40	Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones. BMC Cancer, 2021, 21, 690.	1.1	8
41	Single cell transcriptome revealed tumor associated antigen (TAA) profile in lung adenocarcinoma (LUAD). Biomarker Research, 2021, 9, 41.	2.8	1
42	A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis. Frontiers in Immunology, 2021, 12, 665407.	2.2	20
43	Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypes. Nature Communications, 2021, 12, 3785.	5.8	16
44	METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding. Nature Communications, 2021, 12, 3803.	5.8	74
45	Severe hypoglycemia and finger clubbing in a patient with a BRCA1 mutation in a solitary fibrous tumor: a case report. Annals of Translational Medicine, 2021, 9, 1093-1093.	0.7	3
46	Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB–III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial. Oncologist, 2021, 26, e2151-e2160.	1.9	15
47	Multi-region sequencing reveals genetic correlation between esophageal squamous cell carcinoma and matched cell-free DNA. Cancer Genetics, 2021, 258-259, 93-100.	0.2	2
48	The landscape of m6A regulators in small cell lung cancer: molecular characteristics, immuno-oncology features, and clinical relevance. Molecular Cancer, 2021, 20, 122.	7.9	6
49	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncology, The, 2021, 22, 1265-1274.	5.1	102
50	Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma. Translational Lung Cancer Research, 2021, 10, 18-31.	1.3	8
51	Comparison of surgical difficulty in patients with resectable non-small cell lung cancer under different neoadjuvant treatment modes: a retrospective cohort study. Journal of Thoracic Disease, 2021, 13, 5604-5616.	0.6	6
52	The therapeutic significance of the novel photodynamic material TPE-IQ-20 in tumors. Aging, 2021, 13, 1383-1409.	1.4	9
53	Ferroptosis Characterization in Lung Adenocarcinomas Reveals Prognostic Signature With Immunotherapeutic Implication. Frontiers in Cell and Developmental Biology, 2021, 9, 743724.	1.8	2
54	m6A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. Journal of Hematology and Oncology, 2021, 14, 190.	6.9	36

#	Article	IF	CITATIONS
55	Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nature Communications, 2021, 12, 6770.	5.8	105
56	m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Medicine, 2021, 19, 284.	2.3	23
57	Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Frontiers in Immunology, 2021, 12, 782106.	2.2	O
58	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110619.	1.4	3
59	Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma. Translational Lung Cancer Research, 2021, 11, 0-0.	1.3	2
60	An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer. Cancer Cell International, 2021, 21, 691.	1.8	5
61	Development and validation of a nomogram for predicting survival in patients with surgically resected lung invasive mucinous adenocarcinoma. Translational Lung Cancer Research, 2021, 10, 4445-4458.	1.3	9
62	Three-dimensional reconstruction/personalized three-dimensional printed model for thoracoscopic anatomical partial-lobectomy in stage I lung cancer: a retrospective study. Translational Lung Cancer Research, 2020, 9, 1235-1246.	1.3	24
63	<p>Solid Nodule Appearance as a Predictor of Tumor Spread Through Air Spaces in Patients with Lung Adenocarcinoma: A Propensity Score Matching Study</p> . Cancer Management and Research, 2020, Volume 12, 8197-8207.	0.9	4
64	Collision tumor of the esophagus: a report of five cases. Chinese Medical Journal, 2020, 133, 2386-2388.	0.9	2
65	Prognostic value of tumor-infiltrating lymphocytes in esophageal cancer: an updated meta-analysis of 30 studies with 5,122 patients. Annals of Translational Medicine, 2020, 8, 822-822.	0.7	23
66	An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma. Signal Transduction and Targeted Therapy, 2020, 5, 182.	7.1	21
67	Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma. EBioMedicine, 2020, 59, 102959.	2.7	51
68	Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol. BMC Cancer, 2020, 20, 877.	1,1	1
69	A threeâ€ncRNA signature of pretreatment biopsies predicts pathological response and outcome in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy. Clinical and Translational Medicine, 2020, 10, e156.	1.7	19
70	Preoperative systemic immune-inflammation index and prognostic nutritional index predict prognosis of patients with pulmonary neuroendocrine tumors after surgical resection. Annals of Translational Medicine, 2020, 8, 630-630.	0.7	20
71	Development and validation of an immuneâ€related prognostic signature in lung adenocarcinoma. Cancer Medicine, 2020, 9, 5960-5975.	1.3	79
72	Development of a predictive nomogram for cause-specific mortality in surgically resected early-stage oesophageal cancer: a Surveillance, Epidemiology, and End Results (SEER) analysis. Journal of Thoracic Disease, 2020, 12, 2583-2594.	0.6	5

#	Article	IF	Citations
73	Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics. Journal of Cancer Research and Clinical Oncology, 2020, 146, 821-841.	1.2	22
74	Elevated SLC2A1 Expression Correlates with Poor Prognosis in Patients with Surgically Resected Lung Adenocarcinoma: A Study Based on Immunohistochemical Analysis and Bioinformatics. DNA and Cell Biology, 2020, 39, 631-644.	0.9	15
75	A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma. BMC Cancer, 2020, 20, 130.	1.1	10
76	Postoperative Radiotherapy in Pathological T2–3N0M0 Thoracic Esophageal Squamous Cell Carcinoma: Interim Report of a Prospective, Phase III, Randomized Controlled Study. Oncologist, 2020, 25, e701-e708.	1.9	23
77	Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 2020, 15, 816-826.	0.5	272
78	Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 598437.	1.3	17
79	Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics, 2020, 11, 617174.	1.1	12
80	Treatment outcomes of patients with tracheobronchial mucoepidermoid carcinoma compared with those with adenoid cystic carcinoma. European Journal of Surgical Oncology, 2020, 46, 1888-1895.	0.5	10
81	Bleeding is the most common cause of unplanned return to operating room after lung cancer surgeries. Journal of Thoracic Disease, 2020, 12, 7266-7271.	0.6	4
82	Uniportal versus multiportal thoracoscopic sleeve lobectomy for the surgical treatment of centrally located lung cancer: a single institution experience. Journal of Thoracic Disease, 2020, 12, 7145-7155.	0.6	3
83	Esophageal Squamous Cell Carcinoma Involving the Lip, Back and Hip. Journal of Thoracic Oncology, 2019, 14, 1672-1674.	0.5	1
84	Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. Journal of Cancer, 2019, 10, 3188-3196.	1.2	54
85	Clinicopathological features and prognosis of ciliated muconodular papillary tumor. Journal of Cardiothoracic Surgery, 2019, 14, 143.	0.4	24
86	Tracheobronchial Adenoid Cystic Carcinoma: 50-Year Experience at the National Cancer Center, China. Annals of Thoracic Surgery, 2019, 108, 873-882.	0.7	26
87	Associations of PGK1 promoter hypomethylation and PGK1â€mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€cancer analysis. Cancer Communications, 2019, 39, 1-17.	3.7	23
88	Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy. Annals of Surgical Oncology, 2019, 26, 2890-2898.	0.7	28
89	Adjuvant radiotherapy for stage pN1M0 esophageal squamous cell carcinoma: Results from a Chinese twoâ€center study. Thoracic Cancer, 2019, 10, 1431-1440.	0.8	10
90	Clinicopathological characteristics and prognosis of lung cancer in young patients aged 30 years and younger. Journal of Thoracic Disease, $2019, 11, 4282-4291$ .	0.6	9

#	Article	IF	Citations
91	Effect of intraoperative fluid administration on perioperative outcomes in patients undergoing McKeown esophagogastrectomy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 742-748.	0.7	0
92	Surgery of primary non-small cell lung cancer with oligometastasis: analysis of 172 cases. Journal of Thoracic Disease, 2018, 10, 6540-6546.	0.6	17
93	Long-term survival of the middle and lower thoracic esophageal cancer patients after surgical treatment through left or right thoracic approach. Journal of Thoracic Disease, 2018, 10, 2648-2655.	0.6	16
94	Solitary fibrous tumors of the pleura: A single center experience at National Cancer Center, China. Thoracic Cancer, 2018, 9, 1763-1769.	0.8	12
95	Scoring System to Predict the Risk of Surgical Site Infection in Patients with Esophageal Cancer after Esophagectomy with Cervical Anastomosis. Surgical Infections, 2018, 19, 696-703.	0.7	11
96	Predictors of lymph node metastasis and possible selective lymph node dissection in clinical stage IA non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 4061-4068.	0.6	32
97	Combined targeted ion channel therapy: Can it be an alternative choice for esophageal cancer patients?. Medical Hypotheses, 2018, 117, 59-62.	0.8	4
98	Comparison of shortâ€term outcomes and three yearsurvival between total minimally invasive <scp>M</scp> c <scp>K</scp> eown and dualâ€incision esophagectomy. Thoracic Cancer, 2017, 8, 80-87.	0.8	16
99	Long-term outcomes of 307 patients after complete thymoma resection. Chinese Journal of Cancer, 2017, 36, 46.	4.9	15
100	MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochemical and Biophysical Research Communications, 2017, 482, 582-589.	1.0	154
101	The Society for Translational Medicine: clinical practice guidelines for mechanical ventilation management for patients undergoing lobectomy. Journal of Thoracic Disease, 2017, 9, 3246-3254.	0.6	21
102	The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy. Journal of Thoracic Disease, 2017, 9, 3255-3264.	0.6	47
103	A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis. Oncotarget, 2017, 8, 41102-41112.	0.8	10
104	Experiences in the management of anastomotic leakages and analysis of the factors affecting leakage healing in patients with esophagogastric junction cancer. Journal of Thoracic Disease, 2017, 9, 386-391.	0.6	11
105	Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 5267-5277.	0.6	12
106	Prognostic value of preoperative neutrophil-lymphocyte ratio is superior to platelet-lymphocyte ratio for survival in patients who underwent complete resection of thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 1487-1496.	0.6	13
107	Prognostic value of preoperative serum lactate dehydrogenase in thymic carcinoma. Journal of Thoracic Disease, 2016, 8, 2464-2472.	0.6	10
108	The impact of operative approaches on outcomes of middle and lower third esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2016, 8, 3588-3595.	0.6	8

#	Article	IF	CITATIONS
109	A propensity matched comparison of effects between video assisted thoracoscopic single-port, two-port and three-port pulmonary resection on lung cancer. Journal of Thoracic Disease, 2016, 8, 1469-1476.	0.6	18
110	Updated experiences with minimally invasive McKeown esophagectomy for esophageal cancer. World Journal of Gastroenterology, 2015, 21, 12873.	1.4	43
111	Comparative study of video-assisted thoracic surgery versus open thymectomy for thymoma in one single center. Journal of Thoracic Disease, 2014, 6, 726-33.	0.6	28
112	Comparative study of minimally invasive versus open esophagectomy for esophageal cancer in a single cancer center. Chinese Medical Journal, 2014, 127, 747-52.	0.9	18